Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Encarna, Adrover"'
Autor:
Nerea Fernández de Larrea-Baz, Beatriz Pérez-Gómez, Ángel Guerrero-Zotano, Ana María Casas, Begoña Bermejo, José Manuel Baena-Cañada, Silvia Antolin, Pedro Sánchez-Rovira, Manuel Ramos Vázquez, José Ángel Garcia-Sáenz, Antonio Antón, Montserrat Muñoz, Ana de Juan, Carlos Jara, José Ignacio Chacón, Angels Arcusa, Miguel Gil-Gil, Encarna Adrover, Amparo Oltra, Joan Brunet, Sonia González, Susana Bezares, Virginia Lope, Miguel Martín, Marina Pollán
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract This study evaluates the impact of breast cancer (BC) in health related quality of life (HRQL) and in psychological distress (PD) during the initial phases of the disease and looks for contributing factors. A multicentric case-control study,
Externí odkaz:
https://doaj.org/article/33b3d22231de42aba2eaca043fcc939b
Autor:
Silvia Antolin Novoa, César A Rodríguez, Josefina Cruz, Sara López-Tarruella, Ariadna Tibau, Encarna Adrover, Ana Miguel, Mireia Margelí, Purificación Martínez, María Hernández, Antonio Antón, Álvaro Rodríguez-Lescure, Catalina Falo, Isabel Álvarez, Diego Malón, Raquel Andrés, José L Alonso-Romero, César Gómez, J. José Illaramendi, Ruth Campo, Juan José Miralles, Susana Bezares, Federico Rojo, Angel Guerrero-Zotano
Publikováno v:
Cancer Research. 83:P4-07
Background: Triple negative breast cancer (TNBC) is well known for its more aggressive course and poorer prognosis compared to other BC subtypes. RegistEM study provides real world data to understand the distribution of BC subtypes in the advanced se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd263d24bc1ba75ed50aca54c245b128
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-45
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-45
Autor:
Sara López-Tarruella, Angel Guerrero-Zotano, Josefina Cruz, Silvia Antolin Novoa, Purificación Martínez, María Hernández, César A Rodríguez, J. Ignacio Chacón, Ariadna Tibau, Catalina Falo, Álvaro Rodríguez-Lescure, Mireia Margelí, Sonia Servitja, Raquel Andrés, María Galán-Gramaje, Encarna Adrover, Ana Miguel, Rafael Villanueva, Silvia Varela, Ruth Campo, Mª José Escudero, Susana Bezares, Federico Rojo, Isabel Álvarez
Publikováno v:
Cancer Research. 83:P4-07
Background: Over the last years, the treatment of HER2-positive (HER2+) breast cancer (BC) patients (pts) has been changing because of the development of new anti-HER2 agents. In the current analysis, we describe the features, treatment patterns, pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::899553d6b964d08519e6b9057c90c5e3
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-38
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-38
Autor:
Meritxell Bellet, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Ada Ruiz, Xavier Gonzàlez, Encarna Adrover, Analía Azaro, Maria Valls-Margarit, Josep Lluís Parra, Juan Aguilar, Maria Vidal, Anastasi Martín, Joaquín Gavilá, Santiago Escrivá-de-Romaní, Antonia Perelló, Cristina Hernando, Ainhara Lahuerta, Pilar Zamora, Victoria Reyes, María Alcalde, Helena Masanas, Pamela Céliz, Isabel Ruíz, Miguel Gil, Miguel Àngel Seguí, Lorena de la Peña
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Drug–drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highli
Externí odkaz:
https://doaj.org/article/90c5d8caa4924ce685b690ebd1b8579b
Autor:
Ramon Colomer, Francisca Mulero, José Palacios, Eva Carrasco, Ruth Campo, María José Escudero, Antonio Lopez-Alonso, Alfredo Carrato, Sonia Pernas Simon, Fernando Moreno-Anton, Esther Zamora, Begoña Bermejo, Juan Guerra, Emilio Alba, Antonio Llombart-Cussac, Gemma Viñas, Raquel de Andres, Encarna Adrover, Antonio Gonzalez-Martin, Noelia Martinez-Jánez, Miguel Gil-Gil, José Angel García-Saenz, Javier Cortes, Isabel Calvo, Luis Manso, Ana Lluch, Miguel Quintela-Fandino
CONSORT DIAGRAM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94013593e75979e63b97df5cbe7e9166
https://doi.org/10.1158/1078-0432.22463387
https://doi.org/10.1158/1078-0432.22463387
Autor:
Ramon Colomer, Francisca Mulero, José Palacios, Eva Carrasco, Ruth Campo, María José Escudero, Antonio Lopez-Alonso, Alfredo Carrato, Sonia Pernas Simon, Fernando Moreno-Anton, Esther Zamora, Begoña Bermejo, Juan Guerra, Emilio Alba, Antonio Llombart-Cussac, Gemma Viñas, Raquel de Andres, Encarna Adrover, Antonio Gonzalez-Martin, Noelia Martinez-Jánez, Miguel Gil-Gil, José Angel García-Saenz, Javier Cortes, Isabel Calvo, Luis Manso, Ana Lluch, Miguel Quintela-Fandino
Purpose: We previously detected promising efficacy of neoadjuvant nintedanib (a multityrosine kinase inhibitor, TKI) in early HER2-negative breast cancer. In a preclinical study, we monitored stromal hypoxia with 18F-fluoromisonidazole-positron emiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f0ec11c3cac5902f38dfd563804ff22
https://doi.org/10.1158/1078-0432.c.6525386
https://doi.org/10.1158/1078-0432.c.6525386
Autor:
Ramon Colomer, Francisca Mulero, José Palacios, Eva Carrasco, Ruth Campo, María José Escudero, Antonio Lopez-Alonso, Alfredo Carrato, Sonia Pernas Simon, Fernando Moreno-Anton, Esther Zamora, Begoña Bermejo, Juan Guerra, Emilio Alba, Antonio Llombart-Cussac, Gemma Viñas, Raquel de Andres, Encarna Adrover, Antonio Gonzalez-Martin, Noelia Martinez-Jánez, Miguel Gil-Gil, José Angel García-Saenz, Javier Cortes, Isabel Calvo, Luis Manso, Ana Lluch, Miguel Quintela-Fandino
Figure S1 legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26830a81f452d9617c558d35b368709f
https://doi.org/10.1158/1078-0432.22463384.v1
https://doi.org/10.1158/1078-0432.22463384.v1
Autor:
Ramon Colomer, Francisca Mulero, José Palacios, Eva Carrasco, Ruth Campo, María José Escudero, Antonio Lopez-Alonso, Alfredo Carrato, Sonia Pernas Simon, Fernando Moreno-Anton, Esther Zamora, Begoña Bermejo, Juan Guerra, Emilio Alba, Antonio Llombart-Cussac, Gemma Viñas, Raquel de Andres, Encarna Adrover, Antonio Gonzalez-Martin, Noelia Martinez-Jánez, Miguel Gil-Gil, José Angel García-Saenz, Javier Cortes, Isabel Calvo, Luis Manso, Ana Lluch, Miguel Quintela-Fandino
Hypoxic volumes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6ccaecb05496086ed0d9a538164dcfc
https://doi.org/10.1158/1078-0432.22463375.v1
https://doi.org/10.1158/1078-0432.22463375.v1
Autor:
Isabel Álvarez, Ángel Guerrero-Zotano, Josefina Cruz, Purificación Martínez, María Hernández, César A Rodríguez, Álvaro Rodríguez-Lescure, Silvia Antolín, Encarna Adrover, Raquel Andrés, Catalina Falo, Jose Ignacio Chacón, Ana Miguel, Sonia Servitja, Maria Galán Gramaje, Mireia Margelí Vila, César Gómez Raposo, María Jose Echarri, Rafael Villanueva, Ariadna TIbau Martorell, Silvia Varela Ferreiro, Ruth Campo, Juan Jose Miralles, Susana Bezares, Federico Rojo, Sara López-Tarruella
Publikováno v:
Cancer Research. 82:P1-15
Background: The RegistEM study is a non-interventional study that is providing prospective data from around 1900 ABC pts (females and males) diagnosed with advanced disease between 01/Jan/2016 and 31/Dec/2019, either after recurrence or at 1st diagno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65d74f0735a971447a44d8e6a8f251a9
https://doi.org/10.1158/1538-7445.sabcs21-p1-15-04
https://doi.org/10.1158/1538-7445.sabcs21-p1-15-04
Autor:
Sara López-Tarruella, Ángel Guerrero-Zotano, César A Rodríguez, Josefina Cruz, María Hernández, Encarna Adrover, Álvaro Rodríguez-Lescure, Catalina Falo, Purificación Martínez, Ana Miguel, Raquel Andrés, Silvia Antolín, J. Ignacio Chacón, Jose Luis Alonso Romero, Rafael Villanueva Vázquez, Ana Isabel Ballesteros García, María Galán Gramaje, Diego Malón Jiménez, Silvia Varela Ferreiro, Diana Moreno Muñoz, Ruth Campo, María José Escudero, Susana Bezares, Federico Rojo, Isabel Alvarez
Publikováno v:
Cancer Research. 82:PD4-08
Background: The incidence of breast cancer brain metastases (BCBM) is estimated to be around 5-15%, but necropsies show a much higher incidence (30-50%). Frecuency of BCBM has gradually increase likely as a result from advances in systemic treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::181e953c29e325267a524eef3e68bc59
https://doi.org/10.1158/1538-7445.sabcs21-pd4-08
https://doi.org/10.1158/1538-7445.sabcs21-pd4-08